To his credit Mr. Hakami has blown up the old model and sees that if Medtronic diabetes is going to remain relevant and continue to grow it must expand beyond its legacy insulin pump franchise. He understands what Diabetic Investor has been saying for some time, the insulin pump market is not large enough nor growing fast enough to support all the existing players in the market let alone the many who want to enter this market. If Medtronic diabetes is going to grow it must expand not only to insulin using Type 2's but also non-insulin using Type 2's. Insulin delivery will play a major role yet it must go beyond just insulin delivery.